Key result
Acute application of valsartan had different effects on cardiodynamics in diabetic versus healthy rat hearts but failed to improve hyperglycemia-induced changes in cardiac function.
Why the study?
Inhibition of the renin-angiotensin-aldosterone system reduces cardiovascular and diabetes risk, but the effects of the angiotensin II receptor type 1 inhibitor valsartan on cardiac function and oxidative stress required evaluation.
Does acute perfusion with valsartan improve cardiac function and oxidative stress in streptozotocin-induced diabetic rat hearts?
Does acute perfusion with valsartan improve cardiac function and oxidative stress in streptozotocin-induced diabetic rat hearts?
Acute administration of valsartan does not improve cardiac function in the setting of hyperglycemia-induced changes in a diabetic rat model.
Answers are grounded in this paper and cite their sources.
Acute valsartan shows no benefit in diabetic rat hearts; leaves open chronic ARB effects in human diabetic cardiomyopathy.
Diabetes mellitus is a major risk factor for cardiovascular diseases, while cardiovascular diseases are a leading cause of morbidity and mortality worldwide. The renin–angiotensin– aldosterone system controls renal, cardiovascular, adrenal function and regulates fluid and electrolyte balance as well as blood pressure. Because of his role, inhibition of reninangiotensin-aldosteron system is another therapy approach that reduces the risk of diabetes and cardiovascular disease. In this study, our goal was to evaluate effect of valsartan,as inhibitor of angiotensin II receptor type 1, on cardiac tissue and function, with focus on cardiodynamic and oxidative stress. The present study was carried out on 20 adult male Wistar albino rats (8 week old and with body masses of 180-200 g). Rats were divided randomly into 2 groups (10 animals per group). Healthy animals treated with 1 μM of valsartan and streptozotocin-induced diabetic animals perfused with 1 μM of valsartan 4 weeks after the induction of diabetes. Our results demonstrated that acute application of valsartan has different effect on cardiodynamics in rat heart of diabetic and healthy animals but did not improve cardiac function in hyperglycemia-induced changes. A challenge for further investigations are studies with chronic or acute administration, alone or in combination with other angiotensin-converting-enzyme inhibitor in various models of diabetes.
No takes yet. Share an insight, caveat, or question.
Ravic et al. (2019) studied Streptozotocin-induced diabetes mellitus (n=20). Valsartan vs. Baseline (each heart was its own control) and healthy rats was evaluated on Cardiodynamic parameters (dp/dt max, dp/dt min, SLVP, DLVP, HR, CF) and oxidative stress parameters. Acute application of valsartan had different effects on cardiodynamics in diabetic versus healthy rat hearts but failed to improve hyperglycemia-induced changes in cardiac function.
Synapse has enriched 10 related papers. Consider them for comparative context: